Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Kyowa Hakko Posts Strong Profits for Fiscal Year 2007

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Kyowa Hakko Kogyo Co. said the fiscal year ended March 31 saw strong earnings compared to previous years. The Tokyo-based company also said fiscal year 2007 was the final year of a three-year, medium-term business plan and that the company exceeded plan targets "significantly" for sales and operating income

You may also be interested in...



Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma

China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.

Expansion Into China's Lower-Tier Cities Could Be Growth Driver For Big Pharma

China's smaller cities are emerging rapidly as growth areas, while Big Pharma is still focused mostly on Tier 1 cities such as Shanghai, Beijing and Guangzhou, according to IMS Health.

Japanese Kyowa's Antibody Technology Could Mean Cheaper Development Costs For Amgen - Analysts

TOKYO - The size of the up-front payment that Amgen provided Kyowa Hakko Kogyo this week to gain development and commercialization rights to the Phase I humanized monoclonal antibody KW-0761 for most of the world - except Japan, Korea, China and Taiwan - indicates strong interest in the Japanese company's Potelligent technology, experts say

Related Content

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel